Low high-density lipoprotein cholesterol is not responsible for decreased paraoxonase activity in chronic renal failure

Kidney and Blood Pressure Research

Volumn 35, Issue 4, 2012, Pages 264-272

  Varga, Éva ^a   Seres, Ildikó ^a   Harangi, Mariann ^a   Kárpáti, István ^a   Koncsos, Péter ^a   Sztanek, Ferenc ^a   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Atherosclerosis; Dyslipidemia; High density lipoprotein; Paraoxonase; Renal failure; Renal transplantation

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; AZATHIOPRINE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIACYLGLYCEROL; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER;

ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SPECTROPHOTOMETRY; ADULT; AGED; BLOOD; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; ENZYME ACTIVATION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 84857482215     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000334650     Document Type: Article

References (48)

1. Chan MK, Varghese Z, Moorhead JF: Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 1981; 19: 625-637.
2. Heuck CC, Ritz E: Hyperlipoproteinemia in renal insufficiency. Nephron 1980; 25: 1-7.
3. Rapoport J, Aviram M, Chaimovitz C, Brook JG: Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med 1978; 299: 1326-1329.
4. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E: Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 2003; 60:S13-S21.
5. Kaysen GA: Hyperlipidemia in chronic kidney disease. Int J Artif Organs 2007; 30: 987-992.
6. Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S: Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: A stable isotope study. J Am Soc Nephrol 2004; 15: 1008-1015.
7. Hasselwander O, McMaster D, Damian G, Fogarty A, Maxwell DP, Nicholls P, Young IS: Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998; 44: 179-181.
8. Morena M, Cristol JP, Dantoine T, Carbonneau MA, Descomps B, Canaud B: Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 389-395.
9. Barn K, Laftavi M, Pierce D, Ying C, Boden WE, Pankewycz O: Low levels of high-density lipoprotein cholesterol: An independent risk factor for late adverse cardiovascular events in renal transplant recipients. Transpl Int 2010; 23: 574-579.
10. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918-1927.
11. Zumrutdal A, Baltali M, Micozkadioglu H, Torun D, Sezer S, Ozdemir FN, Haberal M: Determinants of coronary artery disease in nondiabetic hemodialysis patients: A matched case-control study. Ren Fail 2007; 29: 67-71.
12. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082-2088.
13. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoproteins. FEBS Lett 1991; 286: 152-154.
14. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
15. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115: 243-253.
16. Durrington PN, Mackness B, Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-480.
17. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000; 28: 1335-1342.
18. Jakubowski H: Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem 2000; 275: 3957-3962.
19. Simpson NE: Serum arylesterase levels of activity in twins and their parents. Am J Hum Genet 1971; 23: 375-382.
20. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998; 18: 1617.
21. Paragh G, Seres I, Harangi M, Pocsai Z, Asztalos L, Locsey L, Szeles G, Kardos L, Varga E, Karpati I, Adany R: Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease. Nephron Clin Pract 2009; 113:c46-c53.
22. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G: Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996; 247: 71-80.
23. Paragh G, Balogh Z, Seres I, Harangi M, Boda J, Kovacs P: Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia. Clin Drug Invest 2000; 19: 277-282.
24. Mathur S, Devaraj S, Jialal I: Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hypertens 2002; 11: 141-147.
25. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM: A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 1986; 256: 2372-2377.
26. Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138.
27. Schiavon R, Battaglia P, De FE, Fasolin A, Biasioli S, Targa L, Guidi G: HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002; 324: 39-44.
28. Shetty JK, Prakash M, Tripathy S, Verma M, Shashidhar KN, Sureshbabu P: Serum paraoxonase activity and protein thiols in chronic renal failure patients. Asian J Biochem 2007; 2: 274-278.
29. Mackness MI, Hallam SD, Peard T, Warner S, Walker CH: The separation of sheep and human serum A-esterase activity with the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol B 1985; 82: 675-677.
30. Gugliucci L, Mehlhaff K, Kinugasa E, Ogata H, Hermo R, Schulze J, Kimura S: Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis. Correlation with low molecular AGE adducts clearance. Clin Chim Acta 2007; 377: 213-220.
31. Roxborough HE, Millar CA, McEneny J, Young IS: Carbamylation inhibits the ferroxidase activity of ceruloplasmin. Biochem Biophys Res Commun 1995; 214: 1073-1078.
32. Sutherland WH, de Jong SA, Walker RJ: Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: An in vitro study. Nephrol Dial Transplant 2004; 19: 75-82.
33. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B: Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
34. Dirican M, Akca R, Sarandol E, Dilek K: Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004; 17: 813-818.
35. Itahara T, Suehiro T, Ikeda Y, Inoue M , Nakamura T, Kumon Y, Kawada M, Hashimoto K: Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb 2000; 7: 152-158.
36. Juretic D, Tadijanovic M, Rekic B, Simeon-Rudolf V, Reiner E, Baricic M: Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 2001; 42: 146-150.
37. Kalogerakis G, Baker AM, Christov S, Rowley KG, Dwyer K, Winterbourn C, Best JD, Jenkins AJ: Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Clin Sci 2005; 108: 497-506.
38. Paragh G, Asztalos L, Seres I, Balogh Z, Locsey L, Karpati I, Matyus J, Katona E, Harangi M, Kakuk G: Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999; 83: 126-131.
39. Suehiro T, Ikeda Y, Shiinoki T, Inoue M, Kumon Y, Itahara T, Hashimoto K: Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002; 9: 133-138.
40. Paragh G, Seres I, Balogh Z, Varga Z, Karpati I, Matyus J, Ujhelyi L, Kakuk G: The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998; 80: 166-170.
41. Lahrach H, Ghalim N, Taki H, Kettani A, Er-Rachdi L, Ramdani B, Saile R: Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on longterm hemodialysis. J Clin Lipidol 2008; 2: 43-50.
42. Kuchta A, Pacanis A, Kortas-Stempak B, Cwiklinska A, Zietkiewicz M, Renke M, Rutkowski B: Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res 2011; 34: 12-19.
43. Beltowski J: Protein homocysteinylation: A new mechanism of atherogenesis? Postepy Hig Med Dow 2005; 59: 392-404.
44. Jakubowski H: Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000; 130:S377-S381.
45. Prakash M, Phani NM, Kavya R, Supriya M: Paraoxonase: its antiatherogenic role in chronic renal failure. Indian J Nephrol 2010; 20: 9-14.
46. James RW, Leviev I, Righetti A: Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101: 2252-2257.
47. Aviram M, Rosenblat M, Bisgaier CL, Newton RS: Atorvastatin and gemfibrozil metabolites, but not the parent drugs are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-280.
48. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE: Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002; 22: 1329-1333.